











## CLAIMS


1. Use of a reverse transcriptase inhibitor (RTI) in the manufacture of a medicament for treating cancer in patient in need thereof, wherein the RTI is:


, 
, 
,


, 
, 
,



, 
, 
,


, 
, 
, or



and the RTI is to be administered according to a continuous schedule.

2. The use of claim 1, wherein the RTI is:



3. The use of claim 1, wherein the cancer is breast cancer.

4. The use of claim 1, wherein the cancer is colon cancer.

5. The use of claim 1, wherein the cancer is lung cancer.

6. The use of claim 1, wherein the cancer is pancreatic ductal cancer.

7. The use of claim 1, wherein the cancer is prostate cancer.

8. The use of claim 1, wherein the cancer is ovarian cancer.

9. The use of claim 1, wherein the cancer is head and neck cancer.

10. The use of any one of claims 1-9, further comprising administering a therapeutically effective amount of at least one second therapeutic agent useful for treating the cancer.

11. The use of claim 10 for treating breast cancer, wherein the at least one second therapeutic agent is tamoxifen, anastrozole, letrozole, exemestane, trastuzumab, paclitaxel, cyclophosphamide, everolimus, docetaxel, capecitabine, methotrexate, fulvestrant, doxorubicin, pertuzumab, gemcitabine, lapatinib, fluorouracil, palbociclib, abemaciclib, toremifene, eribulin, ado-trastuzumab emtransine, fluoxymesterone, bevacizumab, esterified estrogens, ixabepilone, ribociclib, thiotepa, vinblastine, alpelisib, atezolizumab, fam-trastuzumab deruxtecan, hyaluronidase/trastuzumab, ribociclib/letrozole, talazoparib, sacituzumab or tukatinib.

12. The use of claim 10 for treating colon cancer, wherein the at least one second therapeutic agent is capecitabine, oxaliplatin, fluorouracil, bevacizumab, leucovorin, irinotecan,

regorafenib, cetuximab, panitumumab, tipiracil/trifluridine, ziv-aflibercept, interferon beta-1b, methotrexate, pembrolizumab, bevacizumab-awwb, ramucirumab, ipilmumab, nivolumab, encorafenib, levoleucovorin or bevacizumab-bvzr.

13. The use of claim 10 for treating lung cancer, wherein the at least one second therapeutic agent is etoposide, topotecan, nivolumab, pembrolizumab, atezolizumab, durvalumab, methotrexate, cyclophosphamide, carboplatin, cisplatin, docetaxel, gemcitabine, irinotecan, paclitaxel, pemetrexed, vinblastine, or vinorelbine.

14. The use of claim 10 for treating pancreatic ductal cancer, wherein the at least one second therapeutic agent is gemcitabine, fluorouracil, everolimus, erlotinib, paclitaxel, capecitabine, sunitinib, pancreatin, methotrexate, streptozocin, mitomycin, irinotecan, bevacizumab, cetuximab or olaparib.

15. The use of claim 10 for treating head and neck cancer, wherein the at least one second therapeutic agent is cetuximab, docetaxel, methotrexate, pembrolizumab or nivolumab.

16. The use of claim 10 for treating prostate cancer, wherein the at least one second therapeutic agent is buserelin, degarelix, goserelin, histrelin, leuprolide, relugolix, triptorelin, bicalutamide, flutamide, nilutamide, biraterone acetate, apalutamide, or enzalutamide.

17. The use of claim 1, wherein the patient is (a) not infected with the HIV virus, (b) not suspected of being infected with the HIV virus, (c) not being treated for the HIV virus, and/or (d) not being treated to prevent the HIV virus.

18. A kit for carrying out the use of claim 1, the kit comprising (i) the RTI; and (ii) and instructions for administering the compound to a patient having cancer.